A novel anti-CD47-targeted blockade promotes immune activation in human soft tissue sarcoma but does not potentiate anti-PD-1 blockade

[1]  R. Weissleder,et al.  Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12. , 2022, Immunity.

[2]  A. Italiano,et al.  Improving Immunotherapy Efficacy in Soft-Tissue Sarcomas: A Biomarker Driven and Histotype Tailored Review , 2021, Frontiers in Immunology.

[3]  S. Lewin,et al.  Combination Immune Checkpoint Blockade Enhances IL-2 and CD107a Production from HIV-Specific T Cells Ex Vivo in People Living with HIV on Antiretroviral Therapy , 2021, The Journal of Immunology.

[4]  Jifeng Yu,et al.  Targeting CD47 for cancer immunotherapy , 2021, Journal of Hematology & Oncology.

[5]  A. Sahu,et al.  Immune Checkpoint Inhibitor in First-Line Treatment of Metastatic Renal Cell Carcinoma: A Review of Current Evidence and Future Directions , 2021, Frontiers in Oncology.

[6]  R. Lischke,et al.  Novel Insights into the Immunotherapy of Soft Tissue Sarcomas: Do We Need a Change of Perspective? , 2021, Biomedicines.

[7]  R. Zhou,et al.  Immune checkpoint inhibitors for brain metastases in non-small-cell lung cancer: from rationale to clinical application. , 2021, Immunotherapy.

[8]  Sherine F. Elsawa,et al.  Macrophage Polarization States in the Tumor Microenvironment , 2021, International journal of molecular sciences.

[9]  S. Rottey,et al.  Immune checkpoint inhibitors in treatment of soft-tissue sarcoma: A systematic review and meta-analysis. , 2021, European journal of cancer.

[10]  F. van Coevorden,et al.  Cellular Radiosensitivity of Soft Tissue Sarcoma , 2021, Radiation Research.

[11]  J. Plzák,et al.  Fas-Fas Ligand Interplay in the Periphery of Salivary Gland Carcinomas as a New Checkpoint Predictor for Disease Severity and Immunotherapy Response , 2021, Biomedicines.

[12]  S. Jiao,et al.  Impact of the combined timing of PD-1/PD-L1 inhibitors and chemotherapy on the outcomes in patients with refractory lung cancer , 2021, ESMO open.

[13]  Christine E. Brown,et al.  Harnessing and Enhancing Macrophage Phagocytosis for Cancer Therapy , 2021, Frontiers in Immunology.

[14]  Peng Zhang,et al.  Heterogeneity of Soft Tissue Sarcomas and Its Implications in Targeted Therapy , 2020, Frontiers in Oncology.

[15]  Jin-jian Lu,et al.  Regulation of CD47 expression in cancer cells , 2020, Translational oncology.

[16]  P. Hohenberger,et al.  Prognosis of Patients with Metastatic Soft Tissue Sarcoma: Advances in Recent Years , 2020, Oncology Research and Treatment.

[17]  R. Lischke,et al.  Tumoral and paratumoral NK cells and CD8+ T cells of esophageal carcinoma patients express high levels of CD47 , 2020, Scientific Reports.

[18]  R. Lischke,et al.  Novel therapeutic approaches in the treatment of solitary fibrous tumors: A call for a combination therapy. , 2020, Cancer.

[19]  G. Spolverato,et al.  Defining Which Patients Are at High Risk for Recurrence of Soft Tissue Sarcoma , 2020, Current Treatment Options in Oncology.

[20]  T. Matsushita,et al.  Prognostic influence of the treatment approach for pulmonary metastasis in patients with soft tissue sarcoma , 2020, Clinical & Experimental Metastasis.

[21]  A. Gronchi,et al.  Soft‐tissue sarcoma in adults: An update on the current state of histiotype‐specific management in an era of personalized medicine , 2020, CA: a cancer journal for clinicians.

[22]  Naiqiang Zhu,et al.  Assessing immune infiltration and the tumor microenvironment for the diagnosis and prognosis of sarcoma , 2020, Cancer Cell International.

[23]  C. Evans,et al.  Advances in Anti-Tumor Treatments Targeting the CD47/SIRPα Axis , 2020, Frontiers in Immunology.

[24]  David M. Thomas,et al.  Tumor-associated macrophages and macrophage-related immune checkpoint expression in sarcomas , 2020, Oncoimmunology.

[25]  Yibing Chen,et al.  Tumor-associated macrophages: an accomplice in solid tumor progression , 2019, Journal of Biomedical Science.

[26]  L. Ridnour,et al.  Antisense targeting of CD47 enhances human cytotoxic T-cell activity and increases survival of mice bearing B16 melanoma when combined with anti-CTLA4 and tumor irradiation , 2019, Cancer Immunology, Immunotherapy.

[27]  Patrick B. Schwartz,et al.  Role of radiation therapy for retroperitoneal sarcomas: An eight‐institution study from the US Sarcoma Collaborative , 2019, Journal of surgical oncology.

[28]  N. Hacohen,et al.  PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti-PD-1 resistance , 2019, Nature Immunology.

[29]  A. Bang,et al.  Immunotherapy and radiotherapy for metastatic cancers. , 2019, Annals of palliative medicine.

[30]  J. Wolchok,et al.  Immunotherapy of Melanoma: Facts and Hopes , 2019, Clinical Cancer Research.

[31]  Ralph Weissleder,et al.  Successful Anti‐PD‐1 Cancer Immunotherapy Requires T Cell‐Dendritic Cell Crosstalk Involving the Cytokines IFN‐&ggr; and IL‐12 , 2018, Immunity.

[32]  I. Melero,et al.  Cytokines in clinical cancer immunotherapy , 2018, British Journal of Cancer.

[33]  L. Miller,et al.  Addressing the Adult Soft Tissue Sarcoma Microenvironment with Intratumoral Immunotherapy , 2018, Sarcoma.

[34]  A. Muslimani,et al.  Metastatic Soft Tissue Sarcomas: A Review Of Treatment and New Pharmacotherapies. , 2018, P & T : a peer-reviewed journal for formulary management.

[35]  T. Chieochansin,et al.  Inhibition of IL-10 and TGF-β receptors on dendritic cells enhances activation of effector T-cells to kill cholangiocarcinoma cells , 2018, Human vaccines & immunotherapeutics.

[36]  Steven J. M. Jones,et al.  Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas , 2017, Cell.

[37]  T. Willmer,et al.  Managing sarcoma: where have we come from and where are we going? , 2017, Therapeutic advances in medical oncology.

[38]  Robin L. Jones,et al.  SARC006: Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated Chemotherapy-Naive Malignant Peripheral Nerve Sheath Tumors , 2017, Sarcoma.

[39]  G. In,et al.  Treatment of advanced, metastatic soft tissue sarcoma: latest evidence and clinical considerations , 2017, Therapeutic advances in medical oncology.

[40]  J. Blay,et al.  Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial. , 2017, The Lancet. Oncology.

[41]  J. Leitner,et al.  PD-1 Blockade Promotes Emerging Checkpoint Inhibitors in Enhancing T Cell Responses to Allogeneic Dendritic Cells , 2017, Front. Immunol..

[42]  F. Mornex,et al.  [Immunotherapy and radiotherapy]. , 2017, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.

[43]  Y. Colson,et al.  Management of Sarcoma Metastases to the Lung. , 2016, Surgical oncology clinics of North America.

[44]  I. Weissman,et al.  CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer. , 2016, The Journal of clinical investigation.

[45]  I. Weissman,et al.  Anti-CD47 Treatment Stimulates Phagocytosis of Glioblastoma by M1 and M2 Polarized Macrophages and Promotes M1 Polarized Macrophages In Vivo , 2016, PloS one.

[46]  R. Vonderheide,et al.  CD47 blockade as another immune checkpoint therapy for cancer , 2015, Nature Medicine.

[47]  I. Weissman,et al.  Molecular Pathways: Activating T Cells after Cancer Cell Phagocytosis from Blockade of CD47 “Don't Eat Me” Signals , 2015, Clinical Cancer Research.

[48]  J. Berzofsky,et al.  CD47 in the tumor microenvironment limits cooperation between antitumor T-cell immunity and radiotherapy. , 2014, Cancer research.

[49]  M. von Mehren,et al.  GIST Treatment Options after Tyrosine Kinase Inhibitors , 2014, Current Treatment Options in Oncology.

[50]  Jens-Peter Volkmer,et al.  Anti-CD47 antibody–mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response , 2013, Proceedings of the National Academy of Sciences.

[51]  Luigi Mariani,et al.  Outcome prediction in primary resected retroperitoneal soft tissue sarcoma: histology-specific overall survival and disease-free survival nomograms built on major sarcoma center data sets. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  I. Weissman,et al.  Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells , 2012, Leukemia.

[53]  Andrew H. Beck,et al.  Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma , 2012, Proceedings of the National Academy of Sciences.

[54]  J. Blay,et al.  Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[55]  R. Tibshirani,et al.  The Prognostic Value of Tumor-Associated Macrophages in Leiomyosarcoma: A Single Institution Study , 2011, American journal of clinical oncology.

[56]  Ash A. Alizadeh,et al.  Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma , 2010, Cell.

[57]  L. Mariani,et al.  Aggressive Surgery in Retroperitoneal Soft Tissue Sarcoma Carried Out at High-Volume Centers is Safe and is Associated With Improved Local Control , 2010, Annals of Surgical Oncology.

[58]  A. Skubitz,et al.  Identification of heterogeneity among soft tissue sarcomas by gene expression profiles from different tumors , 2008, Journal of Translational Medicine.

[59]  Robert J. Marinelli,et al.  Prognostic Significance of Macrophage Infiltration in Leiomyosarcomas , 2008, Clinical Cancer Research.

[60]  R. Pollock,et al.  Soft Tissue Sarcomas , 2001, CA: a cancer journal for clinicians.

[61]  B Sundell,et al.  Soft-tissue sarcomas. , 1979, British medical journal.

[62]  Z. Cai,et al.  Immunotherapeutic strategies for sarcoma: current perspectives. , 2020, American journal of translational research.

[63]  Robin L. Jones,et al.  SARC 006 : Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated Chemotherapy-Naive Malignant Peripheral Nerve Sheath Tumors , 2017 .

[64]  E. van den Berg,et al.  Metastasis in Soft Tissue Sarcomas: Prognostic Criteria and Treatment Perspectives , 2004, Cancer and Metastasis Reviews.

[65]  H. Wanebo,et al.  Soft tissue sarcoma. , 1997, Medicine and health, Rhode Island.

[66]  immunotherapeutic strategies with , 2022 .